ArticleFrontiers in microbiology2025
Characterization of a new lytic bacteriophage vB_RanS_GDF21 and its endolysin LysGDF21 with antimicrobial activity against
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction and Characterization of the Novel Engineered Endolysin ALC005: A New Alternative Antimicrobial AgainstMicroorganisms · 2026Article
- Deciphering defensive mechanisms inFrontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: The phage vB_RanS_GDF21 (GDF21) was isolated from feces of a duck farm, and its biological properties were characterized. Whole-genome sequencing was performed using the Illumina NovaSeq 6000 platform, followed by a bioinformatic analysis of the genome. The derived endolysin, LysGDF21 (encoded by Results: Transmission electron microscopy showed that phage GDF21 had an icosahedral symmetric head, and a long, non-contractile tail. It exhibited a 20 min eclipse period, burst size of 74 PFU/infected cell, and stability at pH 5-11 and temperatures below 50 °C. Whole-genome sequencing revealed that GDF21 possesses a double-stranded DNA genome with length of 46,925 bp and G+C content of 35.25%. Among the 75 predicted ORFs, 27 were functionally annotated and no genes associated with virulence or antibiotic resistance were identified. Phylogeny and classification analysis indicated that GDF21 is a member of the class Caudoviricetes and is closely related to Riemerella phage vB_RanS_CRP19. LysGDF21 significantly inhibited biofilm formation and disrupted mature biofilms in Conclusion: The characterization of phage GDF21 enriches the phage database, while the potent anti-biofilm and antibacterial activities of LysGDF21 highlight its therapeutic potential against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.